Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | FOS | P01100 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14221977 | 0.89 | LDHA (0.51) | LDHACA2ALOX15ALOX12CYP3A4 | |
| Phyllanthin SCHEMBL29350279 | 0.81 | LDHA (0.57) | LDHACA2ALOX15ALOX12CYP3A4 | |
| SCHEMBL4072201 | 0.81 | CYP3A4 (0.75) | LDHACA2ALOX15ALOX12CYP3A4 | |
| SCHEMBL4250071 | 0.81 | LDHA (0.57) | LDHACA2ALOX15ALOX12CYP3A4 | |
| Phyllanthin SCHEMBL503799 | 0.81 | LDHA (0.57) | LDHACA2ALOX15ALOX12CYP3A4 | |
| SCHEMBL4249167 | 0.81 | LDHA (0.57) | LDHACA2ALOX15ALOX12CYP3A4 | |
| SCHEMBL11911905 | 0.81 | CYP3A4 (0.75) | LDHACA2ALOX15ALOX12CYP3A4 | |
| SCHEMBL7929029 | 0.79 | LDHA (0.59) | LDHACA2ALOX15ALOX12CYP3A4 | |
| SCHEMBL29209157 | 0.79 | LDHA (0.64) | LDHACA2ALOX15ALOX12CYP3A4 | |
| SCHEMBL7940491 | 0.79 | LDHA (0.59) | LDHACA2ALOX15ALOX12CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044121-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMAECUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170044121-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMAECUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2017-02-16 | — | — | US | disclosed |
| US-9481660-B2 | Tetra-O-substituted butane-bridge modified NDGA derivatives, their synthesis and pharmaceutical use | ERIMOS PHARMACEUTICALS, LLC (US) | 2016-11-01 | — | — | US | disclosed |
| US-9481660-B2 | Tetra-O-substituted butane-bridge modified NDGA derivatives, their synthesis and pharmaceutical use | ERIMOS PHARMACEUTICALS, LLC (US) | 2016-11-01 | — | — | US | disclosed |
| US-20140221384-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMAECUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221384-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMAECUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130053378-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053378-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2013-02-28 | — | — | US | disclosed |
| US-8232277-B2 | Tetra-O-substituted butane-bridge modified NDGA derivatives, their synthesis and pharmaceutical use | ERIMOS PHARMACEUTICALS LLC (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232277-B2 | Tetra-O-substituted butane-bridge modified NDGA derivatives, their synthesis and pharmaceutical use | ERIMOS PHARMACEUTICALS LLC (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232277-B2 | Tetra-O-substituted butane-bridge modified NDGA derivatives, their synthesis and pharmaceutical use | ERIMOS PHARMACEUTICALS LLC (US) | 2012-07-31 | — | — | US | disclosed |
| US-20090306070-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306070-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306070-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2009-12-10 | — | — | US | disclosed |
| EP-2076125-A2 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | Erimos Pharmaceuticals LLC (US) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008042921-A2 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008042921-A2 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044121-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMAECUTICAL USE | PTGES, HPGDS, HPGD | LDHA 242/4885CA2 2074/4885ALOX15 185/4885 |
| US-20090306070-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | PTGES, HPGDS, HPGD | LDHA 266/4885CA2 2275/4885ALOX15 171/4885 |
| US-20140221384-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMAECUTICAL USE | PTGES, HPGDS, HPGD | LDHA 242/4885CA2 2074/4885ALOX15 185/4885 |
| US-20130053378-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | PTGES, HPGDS, HPGD | LDHA 266/4885CA2 2275/4885ALOX15 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.